Cargando…

Cost-Effectiveness of Glucosamine in Osteoarthritis Treatment: A Systematic Review

Osteoarthritis (OA) is a chronic condition that most frequently affects older adults. It is currently the most common disability. The cost of treating an aging population places pressure on the healthcare budget. As a result, it is imperative to evaluate medicines’ cost-effectiveness and, accordingl...

Descripción completa

Detalles Bibliográficos
Autores principales: Vo, Nam Xuan, Le, Ngan Nguyen Hoang, Chu, Trinh Dang Phuong, Pham, Huong Lai, Dinh, Khang Xuan An, Che, Uyen Thi Thuc, Ngo, Thanh Thi Thanh, Bui, Tien Thuy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454215/
https://www.ncbi.nlm.nih.gov/pubmed/37628537
http://dx.doi.org/10.3390/healthcare11162340
_version_ 1785096134962708480
author Vo, Nam Xuan
Le, Ngan Nguyen Hoang
Chu, Trinh Dang Phuong
Pham, Huong Lai
Dinh, Khang Xuan An
Che, Uyen Thi Thuc
Ngo, Thanh Thi Thanh
Bui, Tien Thuy
author_facet Vo, Nam Xuan
Le, Ngan Nguyen Hoang
Chu, Trinh Dang Phuong
Pham, Huong Lai
Dinh, Khang Xuan An
Che, Uyen Thi Thuc
Ngo, Thanh Thi Thanh
Bui, Tien Thuy
author_sort Vo, Nam Xuan
collection PubMed
description Osteoarthritis (OA) is a chronic condition that most frequently affects older adults. It is currently the most common disability. The cost of treating an aging population places pressure on the healthcare budget. As a result, it is imperative to evaluate medicines’ cost-effectiveness and, accordingly, their influence on health resource allocation. Our study aims to summarize the cost and outcome of utilizing glucosamine in OA treatment. Databases like Medline, Cochrane, and Scopus were searched as part of the identification process up until April 2023. Our primary inclusion criteria centered on the economic evaluation of glucosamine in OA treatments, providing an incremental cost-effectiveness ratio (ICER). The Quality of Health Economic Studies (QHES) instrument was applied to grade the quality of the studies. Seven qualified studies that discussed the cost-effectiveness of glucosamine with or without other formulations were selected. All of them demonstrated that glucosamine was cost-effective. There was an increase in quality-adjusted life years (QALYs) when incorporating glucosamine in conventional care. Moreover, patented crystalline glucosamine sulfate (pCGS) was more cost-effective than the other formulations of glucosamine (OFG). Overall, utilizing pCGS was more beneficial than using OFG in terms both of cost and quality of life.
format Online
Article
Text
id pubmed-10454215
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104542152023-08-26 Cost-Effectiveness of Glucosamine in Osteoarthritis Treatment: A Systematic Review Vo, Nam Xuan Le, Ngan Nguyen Hoang Chu, Trinh Dang Phuong Pham, Huong Lai Dinh, Khang Xuan An Che, Uyen Thi Thuc Ngo, Thanh Thi Thanh Bui, Tien Thuy Healthcare (Basel) Review Osteoarthritis (OA) is a chronic condition that most frequently affects older adults. It is currently the most common disability. The cost of treating an aging population places pressure on the healthcare budget. As a result, it is imperative to evaluate medicines’ cost-effectiveness and, accordingly, their influence on health resource allocation. Our study aims to summarize the cost and outcome of utilizing glucosamine in OA treatment. Databases like Medline, Cochrane, and Scopus were searched as part of the identification process up until April 2023. Our primary inclusion criteria centered on the economic evaluation of glucosamine in OA treatments, providing an incremental cost-effectiveness ratio (ICER). The Quality of Health Economic Studies (QHES) instrument was applied to grade the quality of the studies. Seven qualified studies that discussed the cost-effectiveness of glucosamine with or without other formulations were selected. All of them demonstrated that glucosamine was cost-effective. There was an increase in quality-adjusted life years (QALYs) when incorporating glucosamine in conventional care. Moreover, patented crystalline glucosamine sulfate (pCGS) was more cost-effective than the other formulations of glucosamine (OFG). Overall, utilizing pCGS was more beneficial than using OFG in terms both of cost and quality of life. MDPI 2023-08-18 /pmc/articles/PMC10454215/ /pubmed/37628537 http://dx.doi.org/10.3390/healthcare11162340 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Vo, Nam Xuan
Le, Ngan Nguyen Hoang
Chu, Trinh Dang Phuong
Pham, Huong Lai
Dinh, Khang Xuan An
Che, Uyen Thi Thuc
Ngo, Thanh Thi Thanh
Bui, Tien Thuy
Cost-Effectiveness of Glucosamine in Osteoarthritis Treatment: A Systematic Review
title Cost-Effectiveness of Glucosamine in Osteoarthritis Treatment: A Systematic Review
title_full Cost-Effectiveness of Glucosamine in Osteoarthritis Treatment: A Systematic Review
title_fullStr Cost-Effectiveness of Glucosamine in Osteoarthritis Treatment: A Systematic Review
title_full_unstemmed Cost-Effectiveness of Glucosamine in Osteoarthritis Treatment: A Systematic Review
title_short Cost-Effectiveness of Glucosamine in Osteoarthritis Treatment: A Systematic Review
title_sort cost-effectiveness of glucosamine in osteoarthritis treatment: a systematic review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454215/
https://www.ncbi.nlm.nih.gov/pubmed/37628537
http://dx.doi.org/10.3390/healthcare11162340
work_keys_str_mv AT vonamxuan costeffectivenessofglucosamineinosteoarthritistreatmentasystematicreview
AT lengannguyenhoang costeffectivenessofglucosamineinosteoarthritistreatmentasystematicreview
AT chutrinhdangphuong costeffectivenessofglucosamineinosteoarthritistreatmentasystematicreview
AT phamhuonglai costeffectivenessofglucosamineinosteoarthritistreatmentasystematicreview
AT dinhkhangxuanan costeffectivenessofglucosamineinosteoarthritistreatmentasystematicreview
AT cheuyenthithuc costeffectivenessofglucosamineinosteoarthritistreatmentasystematicreview
AT ngothanhthithanh costeffectivenessofglucosamineinosteoarthritistreatmentasystematicreview
AT buitienthuy costeffectivenessofglucosamineinosteoarthritistreatmentasystematicreview